Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management

Abstract Chronic neutrophilic leukemia (CNL) is a rare BCR :: ABL1 ‐negative myeloproliferative neoplasm (MPN) defined by persistent mature neutrophilic leukocytosis and bone marrow granulocyte hyperplasia. Atypical chronic myeloid leukemia (aCML) (myelodysplastic “[ MDS ]/ MPN with neutrophilia ” per World Health Organization [WHO]) is a MDS/MPN overlap disorder featuring dysplastic neutrophilia and circulating myeloid precursors. Both manifest with frequent hepatosplenomegaly and less commonly, bleeding, with high rates of leukemic transformation and death. The 2022 revised WHO classification conserved CNL diagnostic criteria of leukocytosis ≥25 × 10 9 /L, neutrophils ≥80% with <10% circulating precursors, absence of dysplasia, and presence of an activating CSF3R mutation. ICC criteria are harmonized with those of other myeloid entities, with a key distinction being lower leukocytosis threshold (≥13 × 10 9 /L) for cases CSF3R‐ mutated. Criteria for aCML include leukocytosis ≥13 × 10 9 /L, dysgranulopoiesis, circulating myeloid precursors ≥10%, and at least one cytopenia for MDS‐thresholds (ICC). In both classifications ASXL1 and SETBP1 (ICC), or SETBP1 ± ETNK1 (WHO) mutations can be used to support the diagnosis. Both diseases show hypercellular bone marrow due to a granulocytic proliferation, aCML distinguished by dysplasia in granulocytes ± other lineages. Absence of monocytosis, rare/no basophilia, or eosinophilia, <20% blasts, and exclusion of other MPN, MDS/MPN, and tyrosine kinase fusions, are mandated. Cytogenetic abnormalities are identified in ~1/3 of CNL and ~15–40% of aCML patients. The molecular signature of CNL is a driver mutation in colony‐stimulating factor 3 receptor—classically T618I, documented in >80% of cases. Atypical CML harbors a complex genomic backdrop with high rates of recurrent somatic mutations in ASXL1 , SETBP1 , TET2 , SRSF2 , EZH2 , and less frequently in ETNK1 . Leukemic transformation rates are ~10–25% and 30–40% for CNL and aCML, respectively. Overall survival is poor: 15–31 months in CNL and 12–20 months in aCML. The Mayo Clinic CNL risk model for survival stratifies patients according to platelets <160 × 10 9 /L (2 points), leukocytes >60 × 10 9 /L (1 point), and ASXL1 mutation (1 point); distinguishing low‐ (0–1 points) versus high‐risk (2–4 points) categories. The Mayo Clinic aCML risk model attributes 1 point each for: age >67 years, hemoglobin <10 g/dL, and TET2 mutation, delineating low‐ (0–1 risk factor) and high‐risk (≥2 risk factors) subgroups. Management is risk‐driven and symptom‐directed, with no current standard of care. Most commonly used agents include hydroxyurea, interferon, Janus kinase inhibitors, and hypomethylating agents, though none are disease‐modifying. Hematopoietic stem cell transplant is the only potentially curative modality and should be considered in eligible patients. Recent genetic profiling has disclosed CBL , CEBPA , EZH2 , NRAS , TET2 , and U2AF1 to represent high‐risk mutations in both entities. Actionable mutations ( NRAS/KRAS , ETNK1 ) have also been identified, supporting novel agents targeting involved pathways. Preclinical and clinical studies evaluating new drugs (e.g., fedratinib, phase 2) and combinations are detailed.